• Novartis’s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. • The startup already has drug R&D alliances with BridgeBio Pharma, Merck, and Argenx. • The post Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets appeared first on MedCity News .
Article Summaries:
- Novartis has announced a $100 million investment in Unnatural Products, a biotech startup that develops technology to deliver peptide therapeutics to previously “undruggable” targets. The partnership aims to advance next‑generation peptide drugs for cardiovascular disease. Unnatural Products already holds research collaborations with BridgeBio Pharma, Merck, and Argenx, positioning it as a key player in peptide‑based drug discovery. The deal underscores Novartis’s commitment to expanding its pipeline beyond small molecules, leveraging peptide platforms to tackle complex cardiovascular conditions. The announcement was first reported by MedCity News.
Sources: